Ticker brief
CYTK CYTOKINETICS INC
Consumer, Non-cyclical · Biotechnology
last close
$61.23
1 day
-1.8%
14 days
-2.7%
mkt cap
$11.7B
signals 14d
17
authors 14d
10
crowd 14d
+1.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 47% cheap · 14 pctile own 1y | IV/HV 1.33× (as of 2026-10-21) |
| Skew — 25Δ RR 30d | -0.032 35 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +3.97 elevated | 5-session Δ +0.07 (as of 2026-07-09) |
| OI alarm | quiet | last alarm 2026-05-06 (z=2.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-15 · now +0.40 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Pharmdca | C | -3.41 | 4 | +0.57 |
| @BiopharmIQ | B | · | 2 | +0.20 |
| @semodough | C | -1.06 | 2 | +0.20 |
| @Biotech2k1 | A | +1.11 | 2 | +0.35 |
| @Quantumup1 | C | +0.10 | 2 | +0.23 |
| @zohmbastic | C | -2.94 | 1 | +0.40 |
| @OptionsHawk | B | -1.11 | 1 | +0.70 |
| @mathlonning | A | -1.27 | 1 | +0.55 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @spotgamma | A | -2.65 | 1 | +0.25 |
Recent signals17of 17 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @Quantumup1 | +0.40 | William Blair initiated Cytokinetics at Outperform with a $101 DCF valuation and a bullish launch outlook. | -4.2% | tweet ↗ |
| 2026-10-14 | @spotgamma | +0.25 | Highlights upside call-spread positioning before a November 14 FDA catalyst. | -3.5% | tweet ↗ |
| 2026-10-14 | @semodough | +0.40 | B. Riley reiterates a Buy view and $146 target on CYTK with multiple near-term catalysts. | -3.5% | tweet ↗ |
| 2026-10-14 | @Biotech2k1 | +0.30 | Calls ARWR high quality and attractively valued while discussing alternative biotech selections. | -3.5% | tweet ↗ |
| 2026-10-14 | @Quantumup1 | +0.05 | UBS cuts CYTK's target to $104 from $115 while reiterating Buy. | -3.5% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | +0.40 | Calls AXSM and CYTK cheap while disclosing preference for MDGL and MIRM. | -0.6% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 3 aficamten hypertrophic-cardiomyopathy results. | -0.6% | tweet ↗ |
| 2026-10-12 | @mathlonning | +0.55 | Author says CYTK is becoming very attractive despite capital-allocation concerns. | -2.5% | tweet ↗ |
| 2026-10-12 | @semodough | +0.00 | Reports Cytokinetics presenting additional ACACIA-HCM data without describing the results. | -2.5% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.40 | Reports CYTK bouncing from previously identified support. | -1.3% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.65 | Selectively buying biotech names during the pullback. — Explicitly discloses ongoing purchases; ticker output is capped at six. | -1.3% | tweet ↗ |
| 2026-10-08 | @OptionsHawk | +0.70 | Reports a buyer of 1,000 May $65 CYTK calls for $10.60 amid weakness. | -1.3% | tweet ↗ |
| 2026-10-08 | @zohmbastic | +0.40 | RBC raised Cytokinetics' target to $113 from $112 and maintained Outperform. | -1.3% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.45 | Names five commercial-stage biotech companies the author likes on pullbacks. | -1.3% | tweet ↗ |
| 2026-10-08 | @Pharmdca | +0.80 | Adding CYTK shares at $60 support and endorsing ownership on the pullback. — Explicitly reports adding shares at support and calls the discounted stock worth owning. | -1.3% | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | +0.20 | Models very high approval odds for CYTK but only limited expected stock upside. | -6.7% | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | +0.20 | Summarizes modeled November FDA odds and move profiles for three biotech catalysts. | -6.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.